Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial 'at progression' cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

Autor: Isabelle Monnet, Alain Vergnenègre, Gilles Robinet, Henri Berard, Regine Lamy, Lionel Falchero, Sabine Vieillot, Roland Schott, Charles Ricordel, Stephane Chouabe, Pascal Thomas, Radj Gervais, Anne Madroszyk, Samir Abdiche, Anne Marie Chiappa, Laurent Greillier, Chantal Decroisette, Jean Bernard. Auliac, Christos Chouaïd

Publikováno v: Therapeutic Advances in Medical Oncology, Vol 13 (2021)

Background: The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring

Externí odkaz: https://doaj.org/article/a1b5190caa744a0094132ccad24a69d7

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

Autor: Nathalie Baize, Christos Chouaid, Lionel Falchero, Patrick Saulnier, Jean-Bernard Auliac, Roland Schott, Groupe Français de Pneumo-Cancérologie – investigators, Laurent Greillier, R. Lamy, Hervé Le Caer, Jacques Letreut, Jacky Crequit, Gwenaelle Le Garff, A. Madroszyk, Radj Gervais, Margaux Geier, Isabelle Monnet, Patrick-Aldo Renault, Alain Vergnenegre, Henri Berard, Eric Dansin, H. Janicot, Hervé Lena

Publikováno v: The Lancet Oncology. 21:1224-1233

Summary Background Topotecan is currently the only drug approved in Europe in a second-line setting for the treatment of small-cell lung cancer. This study investigated whether the doublet of carboplatin plus etoposide was superior to topotecan as a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b2892288de0f63aa230ce4a3c45fe6
https://doi.org/10.1016/s1470-2045(20)30461-7

First-line afatinib plus cetuximab for EGFR-mutant non–small cell lung cancer: Results from the randomized phase II IFCT-1503 ACE-lung study

Autor: Franck Morin, Judith Raimbourg, Didier Debieuvre, Denis Moro-Sibilot, Elisabeth Quoix, Hugues Morel, Elodie Amour, Olivier Molinier, José Hureaux, Etienne Giroux-Leprieur, Isabelle Rault, Alexis B. Cortot, Benjamin Huret, Josiane Otto, Aldo Renault, L. Moreau, Anne Madroszyk, Sandrine Charpentier, Marc G. Denis, Eric Pichon, Henri Berard, Jacques Cadranel

Publikováno v: Clinical Cancer Research
Clinical Cancer Research, American Association for Cancer Research, 2021, 27 (15), pp.4168-4176. ⟨10.1158/1078-0432.CCR-20-4604⟩
Clinical Cancer Research, 2021, 27 (15), pp.4168-4176. ⟨10.1158/1078-0432.CCR-20-4604⟩

Purpose: Double inhibition of epidermal growth factor receptor (EGFR) using a tyrosine kinase inhibitor plus a monoclonal antibody may be a novel treatment strategy for non–small cell lung cancer (NSCLC). We assessed the efficacy and toxicity of af

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76cc6aa17b0f36d03ffa1da497689d14
https://hal.archives-ouvertes.fr/hal-03401841

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial

Autor: Olivier Molinier, Jaafar Bennouna, L. Moreau, Jean-Charles Soria, Laureen Ribassin-Majed, Stephane Jacquot, Denis Moro-Sibilot, Benjamin Lacas, J.P. Pignon, Franck Morin, Bernard Milleron, Didier Debieuvre, Radj Gervais, Fabrice Barlesi, P.J. Souquet, Hervé Lena, L. Petit, Benjamin Besse, Gérard Zalcman, Julien Mazieres, Henri Berard

Publikováno v: Annals of Oncology. 28:1078-1083

Background Adjuvant treatment in resected stage I non-small-cell lung cancer (NSCLC) is generally not recommended. Pazopanib is an oral tyrosine kinase inhibitor of VEGFR-1/2/3 and PDGFR-α/β. We explored the feasibility and efficacy of adjuvant paz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d6c83ff36fe061a19b27fbdbcdeb806
https://doi.org/10.1093/annonc/mdx070

Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial

Autor: Fabrice Barlesi, Nathalie Cozic, L. Moreau, Henri Berard, Denis Moro-Sibilot, Ludovic Lacroix, Julien Mazieres, Radj Gervais, Cécile Jovelet, Jean-Charles Soria, Elodie Amour, Benjamin Besse, Pierre Jean Souquet, Gérard Zalcman, Virginie Westeel, Olivier Molinier, Jaafar Bennouna, Franck Morin, D. Vasseur

Publikováno v: Journal of Clinical Oncology. 39:8526-8526

8526 Background: MRD aims to detect circulating biomarkers of micrometastatic disease and ultimately predict recurrences. The IFCT-0703 randomized phase II trial failed to show a benefit of 6 months adjuvant pazopanib (P) vs. placebo after resection

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::32ebb56c5acebd3f0fca5e5ac962e325
https://doi.org/10.1200/jco.2021.39.15_suppl.8526